A Single-Arm, Expanded Access Study of Zanubrutinib in Participants With B-cell Malignancies

NO_LONGER_AVAILABLE

Conditions studied: Waldenström Macroglobulinemia

In brief

This is a multicenter expanded access study of zanubrutinib monotherapy for participants with B-cell malignancies who are ineligible to enroll into any available zanubrutinib clinical trials

Key facts

Study ID

NCT04052854

Run by

BeiGene

Last updated by the study team

2024-10-23

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Eisenhower Desert Cardiology Center — Rancho Mirage, California, United States
• Sansum Clinic and Ridley Tree Cancer Center — Santa Barbara, California, United States
• Maryland Oncology Hematology, Pa — Columbia, Maryland, United States
• Dana Farber Cancer Institute — Boston, Massachusetts, United States
• Comprehensive Cancer Centers of Nevada — Las Vegas, Nevada, United States
• Morristown Medical Center — Morristown, New Jersey, United States
• Icahn School of Medicine At Mount Sinai — New York, New York, United States
• Clinical Research Alliance, Inc — Westbury, New York, United States
• Texas Oncology Austin Midtown — Round Rock, Texas, United States
• Texas Oncology Tyler Longview — Tyler, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.